HY007

HY007 is an experimental triple-combination antibiotic therapy being developed by Helperby Therapeutics. It is specifically designed to combat highly antimicrobial-resistant (AMR) Gram-negative bacterial infections, with a particular focus on *Acinetobacter baumannii*. The therapy utilizes a triple-agent approach to overcome existing resistance mechanisms in these difficult-to-treat pathogens, likely employing synergistic interactions to restore or enhance the efficacy of antimicrobial agents. While the specific components of the triple combination have not been publicly disclosed in the company's primary pipeline documentation, HY007 is part of Helperby's strategy to develop 'Antibiotic Resistance Breakers' (ARBs) that can tackle multi-drug resistant species.